Men's Wearhouse Founder: 'Board Has Inappropriately Chosen to Silence My Concerns'
Health Care
featured
Already sluggish health-care inflation is projected to slow down even more in 2014 as consumers, employers and the federal government continue looking to cut medical costs, a new report said Tuesday.
» Read More
More
-
Figuring out why states fared poorly in America’s Top States For Business 2008 takes a bit less work than determining why others did well. It usually comes down to performance and scoring in three key categories, and they happen to be the three with the most impact on the weighting and the overall rankings. Here's the ten worst -- and why.
-
After a knee-jerk reaction to the downside after the closing bell yesterday to the surprising four-cent miss by Genentech, the shares are rallying big time in the early regular trading session.
-
The chief executive explains why her stock has taken such a hit.
-
Like so many people who knew Bobby Murcer or were fans of his, I was so sad to hear the news that he had passed away. I didn't know the man. And I only have vague childhood memories of then-Dodger Stadium announcer John Ramsey saying, "Bobby Murcer", when the "Yankee for Life" was playing for the Giants and Cubs at Chavez Ravine.
-
Diagnostic firms DiaSorin and Biomerier and oil storage company Vopak are three small-cap stocks with promising growth prospects, Dave Dudding, fund manager from Threadneedle Investments, told CNBC.
-
As healthcare comes back in fashion, this stock stands poised to profit.
-
A few weeks ago I blogged about a couple analysts cautioning investors that shares of Irish drugmaker Elan would be volatile surrounding the Alzheimer's conference the end of this month.That has certainly proven to be the case, especially today as the second firm this week initiates coverage of the stock, but this time with a "Sell" rating.
-
Figuring out why states fared poorly in America’s Top States For Business 2008 takes a bit less work than determining why others did well. It usually comes down to performance and scoring in three key categories, and they happen to be the three with the most impact on the weighting and the overall rankings. Here's the ten worst -- and why.
-
Big pharma makes strange bedfellows. Pfizer, Merck and Eli Lilly this morning announced they've launched a joint venture of sorts called, "Enlight Biosciences". They're doing it with the help of the Boston-based VC firm PureTech Ventures.
-
One day does not a full-fledged sector rotation make, but yesterday the big pharma stocks put on a show and in the early going today the curtain hasn't fallen. Pfizer even broke above 18 bucks!
-
Crowding into commodities by investors fleeing stocks will contribute to increased volatility, Peter Toogood, chief investment officer at Crosby Forsyth, told "Squawk Box Europe" on Wednesday.
-
At the risk of being ganged up on by the "Elanians" who will take umbrage with the fact that the biopharma team at Cowen and Company is not initiating coverage of the Irish drugmaker with a "screaming buy," I am blogging about the analysts' 50-page call on the stock today.
-
Cramer continued with his "Cramerican Marine Field Guide to Recessions" reflecting on the 1990 Playbook (the last time we had a financial meltdown) where healthcare stocks, especially biotech were the winners then, and in Cramer's view are likely to do it again.
-
On tonight's show we came back to one of my favorite themes, that the idea of "the market" is at best unhelpful. You have to focus on what the big players in the market are buying and selling, and they almost always go by sector. That's why Jim so often uses the Wall Street as fashion show metaphor.
-
Cramer tells what works in the Wall Street fashion show, what gets the big money guys to turn their heads and say, “ah, I want to own that right now,” or "I want to dump that right now", for the exact situation we’re facing.
-
Shares of Merck, which have lost more than a third of their value so far this year, are under continued pressure this morning. They were at 60 bucks in early January. Today they're trading around $37. Big pharma analyst Rupesh Patel at UBS is downgrading the Dow component from Buy to Neutral because he thinks it's gonna be "range-bound near-term"...
-
Ahead of the long holiday weekend I thought this would be as good a time as any to once again go through the "Pharma's Market" mailbag. A couple of blog readers complained about my "short" story about Amgen.
-
As economies around the world struggle, it's best to stay in defensive areas like health care, according to Markus Ratz, fund manager at Lupus Alpha.
-
Benefits for elderly health-care providers might trickle down a lot further than you think.
-
Winning sectors like coal have taken a hit. Who's on top now?
Most Popular Video
The Fast Money traders share their final trades of the day.
Tuesday, 18 Jun 2013 | 5:00 PM ETAhead of the Fed meeting, the S&P 500 appears headed toward 1,687, StockMonster's Guy Adami says.
Tuesday, 18 Jun 2013 | 6:40 PM ETYou say the name of a stock, and Mad Money's Jim Cramer tells you whether to buy or sell.